{"id":"NCT01767519","sponsor":"Allergan","briefTitle":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-01","primaryCompletion":"2014-09-30","completion":"2015-03-18","firstPosted":"2013-01-14","resultsPosted":"2016-01-12","lastUpdate":"2019-04-23"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder","Urinary Incontinence"],"interventions":[{"type":"BIOLOGICAL","name":"BOTOX®","otherNames":["onabotulinumtoxinA","botulinum toxin Type A"]},{"type":"DRUG","name":"solifenacin","otherNames":["Vesicare"]},{"type":"DRUG","name":"Botox placebo (normal saline)","otherNames":[]},{"type":"DRUG","name":"solifenacin placebo","otherNames":[]}],"arms":[{"label":"BOTOX®","type":"EXPERIMENTAL"},{"label":"solifenacin","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.","primaryOutcome":{"measure":"Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1","timeFrame":"Study Baseline, Week 12","effectByArm":[{"arm":"BOTOX®","deltaMin":4.86,"sd":3.206},{"arm":"Solifenacin","deltaMin":5.23,"sd":3.333},{"arm":"Placebo","deltaMin":4.38,"sd":2.485}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":8,"countries":["United States","Belgium","Canada","Czechia","Germany","Poland","United Kingdom"]},"refs":{"pmids":["28161352","37160401"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":145},"commonTop":["Urinary tract infection","Bacteriuria","Dry mouth","Dysuria","Residual urine volume"]}}